Mefloquine is not recommended for severe malaria infections, particularly infections from "P. falciparum", which should be treated with intravenous antimalarials. Mefloquine does not eliminate parasites in the liver phase of the disease, and people with "P. vivax" malaria should be treated with a second drug that is effective for the liver phase, such as primaquine. Mefloquine is widely used for the treatment of malaria in pregnancy. Limited data suggests that it is safe for this purpose. Resistance to mefloquine is now common around the west border in Cambodia and other parts of Southeast Asia. The mechanism of resistance is by increase
Mefloquine ears. It is therefore not recommended in people with a history of mental health problems or epilepsy. Common side effects include vomiting, diarrhea, headaches, and a rash. It is not recommended in pregnancy unless other options are not available. It should not be used during breast feeding. Mefloquine was developed by the United States Army in the 1970s and came into use in the mid 1980s. It is on the World Health Organization's List of Essential Medicines, the most effective and safe medicines needed in a health system. It is available as a generic medication. The wholesale price in the